临床试验:新型钾离子竞争性酸阻滞剂林那拉赞葡糖醛酸与兰索拉唑治疗糜烂性食管炎的剂量探索研究
这项双盲剂量探索研究纳入内镜确诊的糜烂性食管炎患者,随机接受林那拉赞葡糖醛酸25、50、75或100 mg每日两次或兰索拉唑30 mg每日一次治疗4周。林那拉赞葡糖醛酸各剂量合并的4周愈合率在意向治疗分析中为71.1%,在符合方案分析中为80.9%;兰索拉唑分别为60.6%和59.1%。结论认为林那拉赞葡糖醛酸愈合率高且安全性良好,支持其进一步开发。
要点
- 林那拉赞葡糖醛酸各剂量合并4周愈合率ITT 71.1%、PP 80.9%,兰索拉唑分别为60.6%、59.1%。
- LA A/B级且PPI部分应答者中,最佳林那拉赞葡糖醛酸剂量组愈合率优于兰索拉唑28%;LA C/D级中优于50%以上。
- 结论认为林那拉赞葡糖醛酸愈合率高、安全性良好,支持进一步开发。
核心结论
- 林那拉赞葡糖醛酸与兰索拉唑相比显示出高的4周愈合率,安全性良好,支持其进一步开发。
研究设计与样本
- 双盲剂量探索研究,比较林那拉赞葡糖醛酸与兰索拉唑。
- 纳入内镜确诊(经中心审查委员会验证)的糜烂性食管炎患者,需为LA C/D级,或LA A/B级且至少8周质子泵抑制剂治疗部分应答。
- 随机接受4周林那拉赞葡糖醛酸25、50、75或100 mg每日两次,或兰索拉唑30 mg每日一次,随后4周开放标签兰索拉唑。
- 248例患者随机化,中心审查在筛选内镜检查中确认182例糜烂性食管炎。
主要发现
- 林那拉赞葡糖醛酸各剂量合并的4周愈合率:ITT 71.1%,PP 80.9%。
- 兰索拉唑4周愈合率:ITT 60.6%,PPS 59.1%。
- LA A/B级且PPI部分应答患者中,表现最佳的林那拉赞葡糖醛酸剂量组愈合率优于兰索拉唑28%。
- LA C/D级患者中,表现最佳的林那拉赞葡糖醛酸剂量组愈合率优于兰索拉唑50%以上。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Linaprazan glurate, a potassium-competitive acid blocker, is in development for the treatment of erosive oesophagitis and other acid-related diseases. AIM: To evaluate the 4-week healing rate and safety of four linaprazan glurate dosing regimens in patients with erosive oesophagitis. METHODS: This double-blind, dose-finding study compared linaprazan glurate to lansoprazole. We included patients with endoscopically confirmed erosive oesophagitis (validated by a central review board) if they had Los Angeles (LA) grade C/D or LA grade A/B with partial response to at least 8 weeks of proton pump inhibitor therapy. Patients were randomised to 4 weeks of linaprazan glurate (25, 50, 75 or 100 mg twice daily) or lansoprazole (30 mg once daily), followed by 4 weeks of open-label lansoprazole. RESULTS: Of 248 patients randomised, central review confirmed erosive oesophagitis in 182 at screening endoscopy. Across all doses, linaprazan glurate achieved a 4-week healing rate of 71.1% in intention-to-treat (ITT) analysis and 80.9% in per protocol (PP) analysis. In comparison, lansoprazole achieved healing rates of 60.6% (ITT) and 59.1% (PPS). The best performing linaprazan glurate dosing group outperformed lansoprazole by 28% in patients with LA grade A/B with partial PPI response and by more than 50% in patients with LA grade C/D. CONCLUSIONS: Linaprazan glurate demonstrated high 4-week healing rates compared to lansoprazole, with a good safety profile, supporting its further development. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05055128; EudraCT: 2020-003319-91.
引用
- Sharma P, Vaezi M, Unge P, et al. Clinical Trial: Dose-Finding Study of Linaprazan Glurate, A Novel Potassium-Competitive Acid Blocker, Versus Lansoprazole for the Treatment of Erosive Oesophagitis. Aliment Pharmacol Ther. 2025. PMID: 40183130. doi:10.1111/apt.70109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。